Vizimpro OverviewDacomitinib (PF-00299804) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing. In 201...
Read more Vizimpro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dacomitinib
Recent Vizimpro Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 15mg, 30mg, 45mg
NDC Database Records for Vizimpro: (3 results)Sorted by National Drug Code
- 0069-0197 Vizimpro 15 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
- 0069-1198 Vizimpro 30 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
- 0069-2299 Vizimpro 45 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc